--Sierra Chief Development Officer
Barbara Klencke to be joined by
renowned myelofibrosis experts Jean-Jacques
Kiladjian, Ruben Mesa and
Srdan Verstovsek--
VANCOUVER, BC, Dec. 1, 2020 /CNW/ - Sierra Oncology, Inc.
(SRRA), a late-stage biopharmaceutical company on a quest to
deliver targeted therapies that treat rare forms of cancer, today
announced it will host an analyst and investor event on
Wednesday, December 16, 2020 at
10:00 am ET. The event will feature
three leading myelofibrosis experts:
- Jean-Jacques Kiladjian, MD,
PhD, Saint-Louis Hospital; Paris Diderot University
- Ruben Mesa, MD, Director
of the Mays Cancer Center, home to UT Health San Antonio, MD
Anderson Cancer Center
- Srdan Verstovsek, MD, PhD, University of Texas; MD Anderson Cancer Center
The call will include an overview of momelotinib data presented
at the American Society of Hematology Annual Meeting, a panel
discussion moderated by Barbara
Klencke, MD, Chief Development Officer of Sierra Oncology,
and an open question & answer session with attendees.
Analyst & Investor Event and Webcast Information
Date and Time: Wednesday, December 16,
2020, 10:00 am ET
To register, please click here.
The presentation will be webcast live, and an archive of the
presentation will be accessible after the event through the Sierra
Oncology website: www.SierraOncology.com.
About Momelotinib
Momelotinib is a selective and orally bioavailable JAK1, JAK2
and ACVR1 inhibitor currently under investigation for the treatment
of myelofibrosis. Myelofibrosis results from dysregulated JAK-STAT
signaling and is driven by constitutional symptoms, splenomegaly
(enlarged spleen) and progressive anemia.
Momelotinib is currently under investigation in the MOMENTUM
clinical trial, a global, randomized, double-blind Phase 3 study
for symptomatic and anemic myelofibrosis patients. Top-line data
are anticipated in H1 2022. The U.S. Food & Drug Administration
has granted Fast Track designation for momelotinib.
About Sierra Oncology
Sierra Oncology is a late-stage biopharmaceutical company on a
quest to deliver targeted therapies that treat rare forms of
cancer. We harness our deep scientific expertise to identify
compounds that target the root cause of disease to advance targeted
therapies with assets on the leading edge of cancer biology.
Our team takes an evidence-based approach to understand the
limitations of current treatments and explore new ways to change
the cancer treatment paradigm. Together we are transforming promise
into patient impact.
For more information, visit www.SierraOncology.com.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995, including, but not
limited to, statements regarding Sierra Oncology's expectations
from current data, anticipated clinical development activities,
expected timing and success of enrollment of MOMENTUM and potential
benefits of momelotinib. All statements other than statements of
historical fact are statements that could be deemed forward-looking
statements. These statements are based on management's current
expectations and beliefs and are subject to a number of risks,
uncertainties and assumptions that could cause actual results to
differ materially from those described in the forward-looking
statements. Such forward-looking statements are subject to risks
and uncertainties, including, among others, the risk that Sierra
Oncology's cash resources may be insufficient to fund its current
operating plans and it may be unable to raise additional capital
when needed, the risk that disruptions and impacts of COVID-19 will
be significant and lengthy, Sierra Oncology may be unable to
successfully develop and commercialize momelotinib,
momelotinib may not demonstrate safety and efficacy or
otherwise produce positive results, Sierra Oncology may experience
delays in the clinical development of momelotinib, Sierra Oncology
may be unable to acquire additional assets to build a pipeline of
additional product candidates, Sierra Oncology's third-party
manufacturers may cause its supply of materials to become limited
or interrupted or fail to be of satisfactory quantity or quality,
Sierra Oncology may be unable to obtain and enforce intellectual
property protection for its technologies and momelotinib and the
other factors described under the heading "Risk Factors" set forth
in Sierra Oncology's filings with the Securities and Exchange
Commission from time to time. Sierra Oncology undertakes no
obligation to update the forward-looking statements contained
herein or to reflect events or circumstances occurring after the
date hereof, other than as may be required by applicable law.
View original
content:http://www.prnewswire.com/news-releases/sierra-oncology-to-host-kol-panel-event-to-discuss-updated-phase-3-myelofibrosis-data-presented-at-ash-301182114.html
SOURCE Sierra Oncology